On 22 October 2024, Samsung Biologics announced that it has entered a contract manufacturing deal worth USD 1.24 billion, with an un-named Asia-based pharmaceutical company. The contract extends until December 2037, with production to occur at Samsung Biologics’ biomanufacturing site in Songdo, South Korea.
Samsung reports that this deal brings the value of its contracts for 2024 to over USD 3.3 billion. Prior to this contract, Samsung’s largest contract manufacturing deal was worth USD 1.06 billion and was signed in July 2024 with an un-named US-based pharmaceutical company.